EBioMedicine (Aug 2016)

Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry

  • Raffaello Cimbro,
  • Francis C. Peterson,
  • Qingbo Liu,
  • Christina Guzzo,
  • Peng Zhang,
  • Huiyi Miao,
  • Donald Van Ryk,
  • Xavier Ambroggio,
  • Darrell E. Hurt,
  • Luca De Gioia,
  • Brian F. Volkman,
  • Michael A. Dolan,
  • Paolo Lusso

DOI
https://doi.org/10.1016/j.ebiom.2016.06.037
Journal volume & issue
Vol. 10, no. C
pp. 45 – 54

Abstract

Read online

Tyrosine sulfation is a post-translational modification that facilitates protein-protein interaction. Two sulfated tyrosines (Tys173 and Tys177) were recently identified within the second variable (V2) loop of the major HIV-1 envelope glycoprotein, gp120, and shown to contribute to stabilizing the intramolecular interaction between V2 and the third variable (V3) loop. Here, we report that tyrosine-sulfated peptides derived from V2 act as structural and functional mimics of the CCR5 N-terminus and potently block HIV-1 infection. Nuclear magnetic and surface plasmon resonance analyses indicate that a tyrosine-sulfated V2 peptide (pV2α-Tys) adopts a CCR5-like helical conformation and directly interacts with gp120 in a CD4-dependent fashion, competing with a CCR5 N-terminal peptide. Sulfated V2 mimics, but not their non-sulfated counterparts, inhibit HIV-1 entry and fusion by preventing coreceptor utilization, with the highly conserved C-terminal sulfotyrosine, Tys177, playing a dominant role. Unlike CCR5 N-terminal peptides, V2 mimics inhibit a broad range of HIV-1 strains irrespective of their coreceptor tropism, highlighting the overall structural conservation of the coreceptor-binding site in gp120. These results document the use of receptor mimicry by a retrovirus to occlude a key neutralization target site and provide leads for the design of therapeutic strategies against HIV-1.

Keywords